Dr. Han C. Phan, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
AL license 25990
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $45.30 in total to this clinician.
| Insmed, Inc. | $45.30 |
|---|
| Food and Beverage | $45.30 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 13 companies. The companies reported $2,195,714 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Sarepta Therapeutics, Inc. - Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Ultragenyx Pharmaceutical Inc. · Terminated · NCT06617429 - A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03771898 - Study name not reported
Sarepta Therapeutics, Inc. - Study name not reported
Sarepta Therapeutics, Inc. - Long-term Extension of GTX-102 in Angelman Syndrome
Ultragenyx Pharmaceutical Inc. · Terminated · NCT06415344 - A phase 2, prospective, interventional, open-label, multi-site, extension study to assess the long-term safety and tolerability of TAK-935 (OV935) as adjunctive therapy in patients with rare epilepsy
Takeda Pharmaceuticals U.S.A., Inc. - Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Itf Therapeutics LLC · Recruiting · NCT03373968 - NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Ns Pharma, Inc. - Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Acadia Pharmaceuticals Inc · Completed · NCT06173531
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.